Janssen Submits Application to the EMA to Expand Use of IMBRUVICA® (ibrutinib) in Previously Untreated Chronic Lymphocytic Leukaemia Patients
3.11.2015 14:07 | Business Wire
Janssen-Cilag International NV announced today the submission of a Type II variation application to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorisation for IMBRUVICA® (ibrutinib) to include previously untreated patients with chronic lymphocytic leukaemia (CLL). IMBRUVICA is co-developed by Cilag GmbH International, a member of the Janssen Pharmaceutical Companies, and Pharmacyclics LLC, an AbbVie company. Janssen affiliates market IMBRUVICA in EMEA (Europe, Middle East and Africa) as well as the rest of the world, except for the United States, where Janssen Biotech, Inc. and Pharmacyclics LLC co-market it.
The filing is based on data from the randomised, multi-centre, open-label Phase 3 RESONATETM-2 (PCYC-1115) clinical trial assessing the use of IMBRUVICA versus chlorambucil in patients with treatment-naïve CLL or small lymphocytic lymphoma (SLL) aged 65 years or older.
The RESONATE-2 trial, which was sponsored by Pharmacyclics LLC, enrolled 269 patients in the U.S., EU and other regions. Patients were randomised to receive either IMBRUVICA 420 mg orally, once daily until progression or toxicity, or chlorambucil 0.5 to 0.8 mg/kg on days 1 and 15 of each 28-day cycle for up to 12 cycles. At the time of the final analysis the primary endpoint was met, with IMBRUVICA shown to be superior to chlorambucil in terms of progression-free survival (PFS). In addition, IMBRUVICA demonstrated significant improvements in key secondary efficacy endpoints, including overall survival (OS), overall response rate (ORR) and in haematologic function. The safety findings were consistent with previous studies.
The data have been accepted for presentation at an upcoming medical conference and for publication in a peer-reviewed journal. More information about the study can be found on www.clinicaltrials.gov. On 14 September 2015, Janssen announced that a supplemental New Drug Application (sNDA) was filed with the U.S. Food and Drug Administration for treatment-naïve patients with CLL based on these data.1
“This submission to expand the use of IMBRUVICA for patients with treatment-naïve CLL is a significant step forward in transforming the treatment journey for these patients,” said Jane Griffiths, Company Group Chairman, Janssen Europe, Middle East and Africa. “Our ongoing efforts to further investigate IMBRUVICA in additional populations is part of our commitment to improving outcomes for patients with difficult to manage cancers.”
- ENDS -
About IMBRUVICA ® (ibrutinib)
IMBRUVICA (ibrutinib) is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, which works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B cells.2 By blocking this BTK protein, IMBRUVICA helps kill and reduce the number of cancer cells. It also slows down the worsening of the cancer.3
IMBRUVICA is currently approved in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL); adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line patients with CLL in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy;4 and in adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.4 Regulatory approval for additional uses has not yet been granted. Investigational uses for ibrutinib, alone and in combination with other treatments, are under way in several blood cancers including CLL, MCL, WM, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM) and marginal zone lymphoma (MZL).
IMBRUVICA is co-developed by Cilag GmbH International, a member of the Janssen Pharmaceutical Companies, and Pharmacyclics, LLC, an AbbVie company. Janssen affiliates market IMBRUVICA in EMEA (Europe, Middle East and Africa) as well as the rest of the world, except for the United States, where Janssen Biotech, Inc. and Pharmacyclics LLC co-market it. Janssen and Pharmacyclics are continuing an extensive clinical development programme for IMBRUVICA, including Phase 3 study commitments in multiple patient populations – please see the IMBRUVICA summary of product characteristics for further information.
In most patients, CLL is generally a slow-growing blood cancer of the white blood cells called B-lymphocytes.5 The median age at diagnosis is 72 years,6 and incidence rates among men and women in Europe are approximately 5.87 and 4.01 cases per 100,000 persons per year, respectively.7 CLL is a chronic disease; median overall survival ranges between 18 months and more than 10 years according to the stage of disease.8 The disease eventually progresses in the majority of patients, and patients are faced with fewer treatment options each time. Patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments.
CLL cells are found in both the lymphatic system and the blood.9 When the cancer cells are located mostly in the lymph nodes, the disease is called small lymphocytic lymphoma (SLL). Both CLL and SLL are considered different manifestations of the same entity, as classified in the fourth edition of the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues.10
Janssen in Oncology
In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include a focus on haematologic malignancies, prostate cancer and lung cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment.
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious diseases (e.g., HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
Cilag GmbH International; Janssen Biotech, Inc.; and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
1. Janssen Biotech, Inc. IMBRUVICA® (ibrutinib) Supplemental New Drug Application for Treatment-naive Chronic Lymphocytic Leukemia Submitted to the U.S. FDA. http://www.prnewswire.com/news-releases/imbruvica-ibrutinib-supplemental-new-drug-application-for-treatment-naive-chronic-lymphocytic-leukemia-submitted-to-the-us-fda-300142150.html. Last accessed October 2015.
2. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.
3. European Medicines Agency. How is the medicine expected to work? http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&mid=WC0b01ac058001d12b. Last accessed October 2015.
4. Imbruvica Summary of Product Characteristics, September 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf Last accessed October 2015.
5. American Cancer Society. What is chronic lymphocytic leukemia? Available at: http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-what-is-cll. Last accessed October 2015.
6. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl.6):vi50-vi54.
7. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34.
8. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012;19:18-25.Stilgenbauer S, Zenz T. Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia. Hematology 2010;481-8.
9. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline. Blood. 2013;122:3723-34.
10. Santos FP, O’Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia are they the same disease? Cancer J. 2012;8:396-403.
Mobile: +353 (0)85-744-6696
Phone: +1 732-524-3922
Phone: +1 732-524-6491
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ANA Announces New Online Content "IS JAPAN COOL? DOU"23.8.2017 15:00 | Pressemelding
Today, All Nippon Airways Co., Ltd. (ANA), Japan’s largest and only 5-Star airline, is proud to announce the launch of its new online content “IS JAPAN COOL? DOU,” which illustrates traditional Japanese culture through the use of cutting-edge technology. This content can be seen on “IS JAPAN COOL?,” a website that promotes tourist destinations and popular Japanese cultures to the world. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005024/en/ "IS JAPAN COOL? DOU" TOP (Graphic: Business Wire) While Japan is widely known for its unique pop culture, “IS JAPAN COOL?,” which launched in 2012, has put much of its focus on promoting Japan’s modern culture. As the number of tourists visiting Japan exceeded 24 million people as of 2016, the project aims to provide a deeper understa
Emailage Receives $10 Million Growth Equity Investment to Accelerate Global Expansion23.8.2017 14:00 | Pressemelding
Emailage, the leading provider of global fraud prevention and identity verification using email address scoring, today announced that it has received a $10 million growth equity investment. Anthos Capital led the investment, with participation from Radian Capital, Wipro Ventures, Mucker Capital and Tallwave Capital. Emailage will use the funding to expand existing partnerships, further advance its powerful email address-based predictive scoring system, and accelerate growth in North America, EMEA, LATAM and other key markets. “This investment will allow us to continue our rapid growth, enhance our leadership position in the online fraud detection market and deliver significant fraud prevention capabilities to businesses around the world,” said Emailage CEO Rei Carvalho. Emailage’s Software-as-a-Service solution delivers powerful, real-time risk intelligence by leveraging the
Westinghouse to Provide Fuel to PSEG’s Salem Nuclear Generating Station Through Continued Partnership23.8.2017 12:15 | Pressemelding
Westinghouse Electric Company today announced that it has signed a nuclear fuel contract extension with PSEG, a major supplier of nuclear power in New Jersey, to continue providing fuel assemblies for both units at the Salem Nuclear Generating Station. “Westinghouse has been the single-source fuel provider for PSEG’s Salem plant since its start of operations more than 40 years ago, and we are pleased to continue to support this important and long-standing customer through the delivery of safe, reliable high-performance fuel,” said David Howell, president, Americas Region, and chief growth officer at Westinghouse. “This continued partnership is recognition of our reliable fuel performance and confirmation of the important trust PSEG has in Westinghouse.” Under the terms of the contract, Westinghouse will deliver its 17x17 Robust Fuel Assemblies, known as RFA-2. The design of
GN Hearing Announces Availability of Rechargeable Solution for the Recently Launched ReSound LiNX 3D23.8.2017 12:00 | Pressemelding
GN Hearing introduces a rechargeable battery option for the revolutionary ReSound LiNX 3D hearing aids. Available in North America and other major markets from September 1, the rechargeable battery solution gives ReSound users even more options to choose from. The rechargeable option is also available for Beltone Trust in North America, and from September 1 this will be extended to other major markets. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005211/en/ GN Hearing has made a rechargeable battery option available for the revolutionary ReSound LiNX 3D hearing aids. (Photo: Business Wire) ReSound LiNX 3D Rechargeable – More Than Just Another Rechargeable Hearing Aid The rechargeable battery option is made available based on a deep understanding of user expectations
EURid Supports Uganda Borehole Rehabilitation Project23.8.2017 09:00 | Pressemelding
EURid has announced its support to the Borehole Rehabilitation project in Uganda to provide thousands of people with clean drinkable water. EURid sees water as the most basic requirement for life. For many rural communities across Sub-Saharan Africa it is still a struggle to find safe drinking water. Moreover, water drawn from rivers could potentially contain lethal contaminants and therefore must be boiled before ingestion, adding yet an additional hardship for families as well as the environment in terms of firewood used. The goal of the Borehole Rehabilitation project is to better this situation by working with Ugandan communities to repair broken boreholes and restore access to clean, safe drinking water. The direct benefits of the project are that families no longer have to travel great distances to attain water or boil the water to eradicate contaminants, saving firewood and prev
His Highness Sheikh Mohammed bin Rashid Al Maktoum Unveils Blueprint for Dubai Food Park23.8.2017 07:00 | Pressemelding
His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has unveiled the blueprint for Dubai Food Park (DFP), the latest addition to Dubai Wholesale City (DWSC). This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170823005041/en/ Central Wholesale Market within Dubai Food Park (Photo: AETOS Wire) To be developed at a cost of US$1.5 billion, first destination in the Middle East dedicated to serving the food sector. DFP seeks to enhance Dubai’s position as a leading regional hub for food trade, import, export and re-export of foodstuffs. Conceptualized at a time when food trade makes up 11 percent of the UAE’s GDP and the food industry is estimated to grow by 70 percent to US$6.3 billion by 2030, the Park will offer all categories of f
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom